Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Dr-reddy
CIFLOC 250 (tablets) CIFLOC 500 (tablets) CIFLOC 750 (tablets) SCHEDULING STATUS: S4 PROPRIETARY NAME (and dosage form): CIFLOC 250 (tablets) CIFLOC 500 (tablets) CIFLOC 750 (tablets) COMPOSITION: CIFLOC 250: Each tablet contains ciprofloxacin hydrochloride equivalent to 250 mg ciprofloxacin . CIFLOC 500: Each tablet contains ciprofloxacin hydrochloride equivalent to 500 mg ciprofloxacin. CIFLOC 750: Each tablet contains ciprofloxacin hydrochloride equivalent to 750 mg ciprofloxacin. PHARMACOLOGICAL CLASSIFICATION: A. 20.1.1. Broad and medium spectrum antibiotics. PHARMACOLOGICAL ACTION Ciprofloxacin is a synthetic, 4-quinolone derivative and inhibits gyrase-mediated DNA supercoiling. It has in vitro bactericidal activity against the following Gram-negative and Gram-positive organisms. In vitro sensitivity does not necessarily imply in vivo efficacy. Acinetobacter Haemophilus influenzae Proteus vulgaris Streptococcus pyogenes Aeromonas Haemophilus para-influenzae Providencia rettgeri Streptococcus species Brucella Hafnia Providencia stuartii Vibrio Campylobacter jejuni Klebsiella species Pseudomonas aeruginosa Viridans streptococci Citrobacter freundii Listeria Salmonella enteritidis Yersinia Citrobacter species Moraxella catarrhalis Serratia marcescens Corynebacterium Morganella morganii Shigella flexneri E. coli Neisseria gonorrhoea Shigella sonnei Edwardsiella Pasteurella Staphylococcus aureus Enterobacter cloacae Plesiomonas Staphylococcus epidermidis Enterobacter species Proteus mirabilis Streptococcus faecalis The following organisms show varying degrees of in vitro sensitivity to ciprofloxacin: Alcaligenes, Enterococcus faecalis, Flavobacterium, Gardnerella, Legionella, Mycobacterium fortuitum, Mycobacterium tuberculosis, Mycoplasma hominis, Streptococcus agalactiae, Chlamydia. The following organisms are usually resistant: Enterococcus Read the complete document